Common Antihypertensive Treatments: Doses and Contraindications
For most patients with confirmed hypertension (BP ≥140/90 mmHg), initiate treatment with a two-drug combination from first-line classes: thiazide-type diuretics, ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), or long-acting dihydropyridine calcium channel blockers (CCBs), preferably as a single-pill combination. 1, 2
First-Line Antihypertensive Agents
Thiazide-Type Diuretics
Chlorthalidone:
- Dose: 12.5-25 mg once daily 1
- Key advantage: Longer half-life and more potent than hydrochlorothiazide on a mg-to-mg basis
- Monitoring: Watch for hyponatremia, hypokalemia, hyperglycemia, hyperuricemia, and hypercalcemia
- Contraindications: History of acute gout (unless patient is on urate-lowering therapy) 1
Hydrochlorothiazide (HCTZ):
- Dose: 25-50 mg once daily 1
- Note: Shorter-acting than chlorthalidone; recent pragmatic RCT showed no difference in MACE when switching from HCTZ to chlorthalidone in general population, though subgroup with ASCVD benefited more from chlorthalidone 1
Indapamide:
- Dose: 1.25-2.5 mg once daily 1
ACE Inhibitors
Common agents with typical dosing 1:
- Lisinopril: 10-40 mg once daily
- Enalapril: 5-40 mg once or twice daily
- Benazepril: 10-40 mg once or twice daily
- Quinapril: 10-80 mg once or twice daily
- Fosinopril: 10-40 mg once daily
Key contraindications:
- Pregnancy (teratogenic)
- Bilateral renal artery stenosis
- History of angioedema
- Never combine with ARB and/or renin inhibitor (Class 3 Harm recommendation - increases risk of hyperkalemia, hypotension, and renal dysfunction) 1
Monitoring: Serum creatinine and potassium within 2-4 weeks of initiation
Angiotensin Receptor Blockers (ARBs)
Common agents with typical dosing 1:
- Losartan: 50-100 mg once daily
- Valsartan: 80-320 mg once daily
- Irbesartan: 150-300 mg once daily
- Olmesartan: 20-40 mg once daily
- Telmisartan: 40-80 mg once daily
- Candesartan: 8-32 mg once daily
Contraindications: Same as ACEi (pregnancy, bilateral renal artery stenosis, combination with ACEi or renin inhibitor) 1, 2
Advantage over ACEi: Lower incidence of cough and angioedema
Long-Acting Dihydropyridine Calcium Channel Blockers
Amlodipine:
- Dose: 2.5-10 mg once daily
- Most commonly used CCB in combinations 1
Nifedipine (extended-release):
- Dose: 30-90 mg once daily
Non-dihydropyridine CCBs (Verapamil, Diltiazem):
- Verapamil SR: 120-480 mg once daily
- Diltiazem SR: 120-360 mg once daily
- Note: Useful for rate control but avoid in heart failure with reduced ejection fraction
Contraindications for CCBs:
- Severe aortic stenosis
- Heart failure with reduced ejection fraction (for non-dihydropyridines)
- Severe gastroesophageal reflux disease (relative contraindication for dihydropyridines) 3
Common side effect: Peripheral edema (reduced when combined with ACEi or ARB) 1
Treatment Initiation Strategy
Stage 2 Hypertension (BP ≥140/90 mmHg)
Start with two-drug combination (Class 1 recommendation): 1, 2
- Preferred combinations:
- ACEi or ARB + thiazide-type diuretic
- ACEi or ARB + dihydropyridine CCB
- CCB + thiazide-type diuretic
Use single-pill combinations when possible to improve adherence 1, 2
Stage 1 Hypertension (BP 130-139/80-89 mmHg)
Monotherapy is reasonable with dose titration and sequential addition as needed 1
Exception: If high cardiovascular risk (≥7.5% 10-year risk), consider initiating treatment even at lower BP thresholds 4
Escalation to Three-Drug Therapy
If BP not controlled on two drugs, advance to: 1, 2
- ACEi or ARB + dihydropyridine CCB + thiazide-type diuretic
- Preferably as single-pill combination
Second-Line and Adjunctive Agents
Beta-Blockers
Use when compelling indications exist: 2
- Post-myocardial infarction
- Heart failure with reduced ejection fraction
- Angina
- Atrial fibrillation requiring rate control
Common agents:
- Metoprolol succinate: 50-200 mg once daily
- Carvedilol: 6.25-25 mg twice daily
- Bisoprolol: 2.5-10 mg once daily
- Atenolol: 25-100 mg once daily
Contraindications:
- Severe asthma or COPD with bronchospasm 3
- High-degree AV block (without pacemaker)
- Severe bradycardia
- Decompensated heart failure
Note: Safe in mild-to-moderate intermittent claudication but avoid in rest pain or limb ischemia 3
Mineralocorticoid Receptor Antagonists (MRAs)
Spironolactone:
- Dose: 12.5-50 mg once daily
- Use: Resistant hypertension (fourth-line agent)
- Contraindications: Severe renal impairment (eGFR <30), hyperkalemia (K+ >5.0 mEq/L)
- Monitoring: Potassium and creatinine closely
Eplerenone:
- Dose: 50-100 mg once daily
- Advantage: Less gynecomastia than spironolactone
Blood Pressure Targets
Target BP for most adults: <130/80 mmHg 1, 2
Intensive target (SBP <120 mmHg): Consider in high-risk patients when feasible and well-tolerated 1, 2
Target range per 2024 ESC guidelines: Systolic BP 120-129 mmHg in most adults 2
Important caveat: Individualize for patients with:
- Age ≥85 years
- Symptomatic orthostatic hypotension
- Moderate-to-severe frailty
- Limited life expectancy
- Poor treatment tolerance
Use "as low as reasonably achievable" (ALARA) principle when intensive targets not tolerated 2
Critical Contraindications and Monitoring
Absolute Contraindications to Combination Therapy
Never combine ACEi + ARB + renin inhibitor (Class 3 Harm) 1, 2
- Increases risk of hyperkalemia, hypotension, syncope, and acute kidney injury without additional benefit
Drug-Specific Monitoring Requirements
All RAS blockers (ACEi/ARB):
- Baseline and follow-up creatinine and potassium
- Acceptable creatinine increase: up to 30% from baseline
- Hold if potassium >5.5 mEq/L
Thiazide diuretics:
- Electrolytes (sodium, potassium)
- Glucose and uric acid
- More frequent monitoring in elderly
MRAs:
- Potassium weekly initially, then monthly
- Creatinine monitoring
Special Populations
Diabetes
- Preferred agents: ACEi or ARB (renoprotective) 3
- Target BP: <130/80 mmHg
Chronic Kidney Disease
- Preferred agents: ACEi or ARB (slow progression)
- Caution: Monitor creatinine and potassium closely
Post-Myocardial Infarction
- Preferred agents: Beta-blocker + ACEi or ARB
Heart Failure with Reduced Ejection Fraction
- Preferred agents: ACEi or ARB + beta-blocker + MRA + diuretic
Adherence Strategies
Evidence-based approaches to improve adherence: 1
- Single-pill combinations over separate pills
- Dose consolidation (once-daily dosing)
- Medication synchronization
- Home BP monitoring with feedback
- Pharmacist education and coaching
- Shared decision-making incorporating patient preferences
Timing of medication: Take at most convenient time for patient to establish habitual pattern; no evidence that bedtime dosing superior to morning dosing 2